Truist analyst Joon Lee downgraded Adverum Biotechnologies (ADVM) to Hold from Buy with a $5 price target after Eli Lilly (LLY) agreed to acquire Adverum for $3.56 per share in cash upfront and a $8.91 CVR for a total per share consideration of up to $12.47. The deal “undervalues ixo-vec in our view,” but given the company’s limited operational runway, the firm views it as “a good outcome,” the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADVM: